Correction: J&J Sales

Executive Summary

In the story "Private Grünenthal Aims For Leadership In Pain," (Feb. 21, 2011), "The Pink Sheet" incorrectly reported that the smallest drug on a list of reported drug revenues from Johnson & Johnson for 2010 sold $116 million worldwide. That figure was in fact for fourth quarter 2010 sales. Sales of the oral analgesic Nucynta (tapentadol) seem to be below this apparent reporting threshold, but J&J says it is "pleased" with the drug's performance. "In the two years since the product was approved by FDA, health care professionals have written more than half a million prescriptions for Nucynta, as documented in the IMS National Prescription Audit," the firm states. "In addition, in terms of market share (dollars) for short-acting CII opioids, Nucynta has experienced continued growth for the past four quarters, according to IMS National Sales Perspectives."